Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capivasertib + paclitaxel
- Development stage
- Phase 3
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Capivasertib (AZD5363) is a highly potent, selective oral small molecule inhibitor of the serine/threonine kinase AKT (protein kinase B), with activity against all three isoforms—AKT1, AKT2, and AKT3. It blocks the PI3K/AKT signaling pathway that is frequently activated in various cancers including breast cancer. Paclitaxel is a well-established chemotherapeutic agent that stabilizes microtubules and inhibits cell division. The combination of capivasertib and paclitaxel has been investigated in clinical trials for advanced or metastatic breast cancer—including estrogen receptor-positive (ER+) and triple-negative breast cancer (TNBC)—to assess whether inhibition of the PI3K/AKT pathway can enhance sensitivity to chemotherapy. Capivasertib may be particularly effective in tumors with PIK3CA mutations or PTEN loss[1][2][5][6].
- Other names
- capivasertib + paclitaxel
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)AKT2 (Rac-beta serine/threonine-protein kinase)AKT3 (RAC-gamma serine/threonine-protein kinase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on capivasertib + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capivasertib + paclitaxel.